rationale for mek/braf combinations in melanoma
Published 6 years ago • 409 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
6:22
braf and mek in melanoma
-
1:33
dr. paul chapman on braf and mek inhibitor combination for advanced melanoma
-
2:10
combined treatment with braf and mek inhibitors in metastatic melanomas with braf mutations
-
6:44
case 2: long-term braf/mek data in melanoma
-
9:49
melanoma: nuances of braf/mek combinations in the front line
-
3:19
future combination strategies for braf-mutant melanoma
-
9:24
anti-pd1 monotherapy or combination with ipi after braf/mek inhibitors in braf-mutant melanoma
-
1:19
dr. postow on braf and mek inhibitor combination studies in melanoma
-
3:19
encorafenib in a combination regimen for braf melanoma
-
2:02
mek inhibitors for melanoma: new combination approved
-
22:44
braf targeted therapy - melanoma education symposium, peter boasberg md
-
8:40
melanoma: braf/mek targeted therapy
-
8:47
braf/mek inhibitors in metastatic melanoma
-
1:24
adverse events with dabrafenib/trametinib combination in melanoma
-
1:28
jeffrey weber, md, phd: the impact of braf/mek inhibitors in melanoma
-
1:24
adverse events with dabrafenib/trametinib combination in melanoma
-
1:03
five-year os data for dabrafenib/trametinib combo in melanoma
-
1:06:50
everything you want to know about the braf/mek combination
-
1:03
dr. wilson on choosing between braf/mek therapies for patients with melanoma